These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6149136)

  • 1. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro.
    Richelson E; Nelson A
    Eur J Pharmacol; 1984 Aug; 103(3-4):197-204. PubMed ID: 6149136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro.
    Richelson E; Nelson A
    J Pharmacol Exp Ther; 1984 Jul; 230(1):94-102. PubMed ID: 6086881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroleptic binding to muscarinic M2 receptors of normal human heart in vitro and comparison with binding to M1 and dopamine D2 receptors of brain.
    Neeper R; Richelson E; Nelson A
    Neuropharmacology; 1991 May; 30(5):527-9. PubMed ID: 1678146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroleptic binding to human brain receptors: relation to clinical effects.
    Richelson E
    Ann N Y Acad Sci; 1988; 537():435-42. PubMed ID: 2904784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropharmacology of zotepine, an antimanic drug: a potent blocker of D2 and 5-HT2 receptors of human brain.
    Kanba S; Yagi G; Oguchi E; Nakaki T; Kato R; Richelson E
    Jpn J Psychiatry Neurol; 1991 Mar; 45(1):133-4. PubMed ID: 1684393
    [No Abstract]   [Full Text] [Related]  

  • 6. Neuroleptics have identical potencies in human brain limbic and putamen regions.
    Seeman P; Ulpian C
    Eur J Pharmacol; 1983 Oct; 94(1-2):145-8. PubMed ID: 6140171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro.
    Wander TJ; Nelson A; Okazaki H; Richelson E
    Eur J Pharmacol; 1987 Nov; 143(2):279-82. PubMed ID: 2891550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of neuroleptic compounds at alpha 2-adrenergic receptor affinity states in bovine caudate nucleus.
    Perry BD; Simon PR; U'Prichard DC
    Eur J Pharmacol; 1983 Nov; 95(3-4):315-8. PubMed ID: 6140181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography.
    Schotte A; Janssen PF; Megens AA; Leysen JE
    Brain Res; 1993 Dec; 631(2):191-202. PubMed ID: 7510574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency.
    Peroutka SJ; Synder SH
    Am J Psychiatry; 1980 Dec; 137(12):1518-22. PubMed ID: 6108081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds.
    Richelson E; Souder T
    Life Sci; 2000 Nov; 68(1):29-39. PubMed ID: 11132243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of neuroleptics in use in the United States.
    Richelson E
    J Clin Psychiatry; 1985 Aug; 46(8 Pt 2):8-14. PubMed ID: 2862140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of dopamine receptors in the mechanism of action of neuroleptics].
    Lavretskaia EF; Kats MM; Baldenkov GN
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(3):431-5. PubMed ID: 2859724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro.
    Bymaster FP; Nelson DL; DeLapp NW; Falcone JF; Eckols K; Truex LL; Foreman MM; Lucaites VL; Calligaro DO
    Schizophr Res; 1999 May; 37(1):107-22. PubMed ID: 10227113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors.
    Chivers JK; Gommeren W; Leysen JE; Jenner P; Marsden CD
    J Pharm Pharmacol; 1988 Jun; 40(6):415-21. PubMed ID: 2901473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal neuroleptic/dopamine receptors in schizophrenia.
    Lee T; Seeman P
    Adv Biochem Psychopharmacol; 1980; 21():435-42. PubMed ID: 6103653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone.
    Leysen JE; Janssen PM; Gommeren W; Wynants J; Pauwels PJ; Janssen PA
    Mol Pharmacol; 1992 Mar; 41(3):494-508. PubMed ID: 1372084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coactivation of dopamine D1 and D2 receptors increases the affinity of cholecystokinin-8 receptors in membranes from post-mortem human caudate-putamen.
    von Euler G; Mailleux P; von Euler M; Schiffmann SN; Vanderhaeghen JJ; Fuxe K
    Brain Res; 1992 Jul; 584(1-2):157-62. PubMed ID: 1325243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroleptic affinities for human brain receptors and their use in predicting adverse effects.
    Richelson E
    J Clin Psychiatry; 1984 Aug; 45(8):331-6. PubMed ID: 6146602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevation of brain neuroleptic/dopamine receptors in schizophrenia.
    Lee T; Seeman P
    Am J Psychiatry; 1980 Feb; 137(2):191-7. PubMed ID: 6101525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.